Chong Kun Dang Pharmaceutical Corp.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
3
Ending by 2030
Sep 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 19, 2027The maintenance fee for Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate (US 11,759,428) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 4 fees due May 3 to 28, 2027 · next May 3
- 1 fee due Jun 3, 2027The maintenance fee for Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same (US 10,494,355) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
- 1 fee due Jul 21, 2027The maintenance fee for 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same (US 10,538,498) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.
- 2 fees due Sep 5 to 10, 2027 · next Sep 5
- 1 fee due Oct 16, 2027The maintenance fee for 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same (US 11,958,844) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Nov 17 US 12,799,104 Novel Compounds as Histone Deacetylase 6 Inhibitor, and Pharmaceutical Composition Comprising the Same
- 1 term has ended since Aug 23, 2026
- Aug 23 US 11,420,950 Heterocyclicalkyl Derivative Compounds as Selective Histone Deacetylase Inhibitors and Pharmaceutical Compositions Comprising the Same · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,053,439 | Benzophenone derivatives useful for inhibiting formation of microtubule In force · USPTO record | In force | USPTO record | |
| US 8,178,697 | Method for the preparation of atorvastatin and intermediates used therein In force · USPTO record | In force | USPTO record | |
| US 8,362,267 | Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same In force · USPTO record | In force | USPTO record | |
| US 9,526,787 | Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same In force · USPTO record | In force | USPTO record | |
| US 9,173,853 | Composition for gene delivery In force · USPTO record | In force | USPTO record | |
| US 9,994,627 | Methods for purifying erythropoietin analogs having lower isoelectric point In force · USPTO record | In force | USPTO record | |
| US 9,493,430 | Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors In force · USPTO record | In force | USPTO record | |
| US 11,318,215 | Composition for gene delivery comprising chitosan and liquid crystal formation material In force · USPTO record | In force | USPTO record | |
| US 9,839,207 | Animal model of Charcot-Marie-Tooth disease as HSP27 mutant (S135F) carrier In force · USPTO record | In force | USPTO record | |
| US 9,878,986 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 32: 2 patents in force now held by others · 17 lapsed for an unpaid fee · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending · 4 abandoned · 25 no status recorded